Načítá se...
Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients
Human primary glioblastomas (GBM) often harbor mutations within the epidermal growth factor receptor (EGFR). Treatment of EGFR-mutant GBM cell lines with the EGFR/HER2 tyrosine kinase inhibitor lapatinib can effectively induce cell death in these models. However, EGFR inhibitors have shown little ef...
Uloženo v:
| Vydáno v: | PLoS Comput Biol |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Public Library of Science
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5766249/ https://ncbi.nlm.nih.gov/pubmed/29293494 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pcbi.1005924 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|